Latest investigations into retatruptide peptide highlight promising outlook for treating excess body and type disease. The peptide, a dual stimulator of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, appears to present greater weight reduction and glycemic regulation compared existing medications. Further clinical trials